The 2025 IASLC World Conference on Lung Cancer, held in Barcelona, Spain, in September 2025, gathered over 7,000 global experts and shared over 2,000 abstracts in lung cancer and thoracic oncology. During the Presidential Symposium, Dr David Planchard (Institut Gustave Roussy , Villejuif, France) shared the overall survival (OS) findings from the FLAURA2 trial. This landmark study showed that combining chemotherapy with osimertinib delivers a survival benefit in the first-line treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), representing an important step forward in patient care.
Below, we hear from Drs Igor Gómez-Randulfe and Federico Monaca (The Christie NHS Foundation Trust, Manchester, UK), sharing their insights and key takeaways from the trial.
The final FLAURA2 analysis confirms that osimertinib plus platinum–pemetrexed improves OS versus osimertinib alone, extending median survival to nearly four years and reducing the risk of death. Adding carboplatin and pemetrexed to first-line osimertinib gave a clear, clinically meaningful OS benefit, with median survival close to four years. That sets a new benchmark in EGFR-mutant advanced NSCLC. The key debate was who actually needs upfront intensification and how to tailor it to disease burden, comorbidities, and patient preference.
On the same day that the FLAURA2 results were presented and published, the MARIPOSA results of amivantamab plus lazertinib were also released, showing an equally impressive improvement in OS. Clinical guidelines will endorse these combinations as preferred first-line options for fit patients prioritising maximal OS, particularly those with high disease burden or early progression risk, while retaining osimertinib monotherapy for individuals aiming to minimise chemotherapy exposure or with comorbidities. Shared decision-making will be crucial: the OS gain must be balanced against added toxicity and treatment logistics. Overall, FLAURA2 sets a new survival benchmark and will likely shift the default towards upfront intensification for many patients.
The final FLAURA2 analysis shows a clinically meaningful OS benefit with osimertinib + platinum/pemetrexed over osimertinib alone (47.5 vs 37.6 months; HR 0.77), with 2-, 3- and 4-year OS rates consistently favouring the combination. Practically, this raises the bar for fit, symptomatic, or high-burden EGFR-mutant patients, especially those at risk of early CNS or extrathoracic progression. The trade-off is added chemotherapy toxicity and clinic time; for frailer patients with indolent disease, osimertinib monotherapy remains reasonable. Shared decision-making should integrate fitness, comorbidities and goals, with proactive toxicity mitigation (antiemetics, growth-factor support) and CNS surveillance. As OS improves, attention to post-progression sequencing and resistance biology (e.g., MET amplification) will be crucial to preserve downstream options and open paths to novel combinations. Overall, these data will likely tighten guideline language toward the combination as a front-line standard for most of the patients.
Disclosure:Igor Gómez-Randulfe has received grant/research support from Janssen and is a member of the Advisory Board for Janssen and AstraZeneca. Federico Monaca has no financial or non-financial conflicts of interest to declare in relation to this article.
Cite: WCLC 2025 highlights: Practice-changing FLAURA2 sets new survival benchmark in NSCLC. touchONCOLOGY. September 18th, 2025
Related content
- #ASCO25: What’s new and what matters in NSCLC
- Central Nervous System as a Sanctuary for Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer
- FDA Priority Review fast-tracks zongertinib for advanced NSCLC patients
SIGN UP to touchONCOLOGY!
Join our global community today for access to thousands of peer-reviewed articles, expert insights, and learn-on-the-go education across 150+ specialties, plus concise email updates and newsletters so you never miss out.
